An update from Tonix Pharma ( (TNXP) ) is now available.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Tonix Pharmaceuticals has partnered with the Kenya Medical Research Institute to launch a Phase I clinical trial for its TNX-801 vaccine aimed at preventing mpox and smallpox. This collaboration will see Tonix sponsoring the trial while KEMRI leads its execution, marking a significant step in vaccine development and regulatory approval processes. Investors should note that this announcement includes forward-looking statements about the company’s future operations and market potential.
Learn more about TNXP stock on TipRanks’ Stock Analysis page.
